Synonym
Etoglucid; ICI32865; ICI-32865; ICI 32865
IUPAC/Chemical Name
1,12-di(oxiran-2-yl)-2,5,8,11-tetraoxadodecane
InChi Key
UMILHIMHKXVDGH-UHFFFAOYSA-N
InChi Code
InChI=1S/C12H22O6/c1(13-3-5-15-7-11-9-17-11)2-14-4-6-16-8-12-10-18-12/h11-12H,1-10H2
SMILES Code
C1(CO1)COCCOCCOCCOCC2CO2
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
To be determined
Shelf Life
>2 years if stored properly
Drug Formulation
To be determined
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Preparing Stock Solutions
The following data is based on the
product
molecular weight
262.30
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Flamm J, Donner G, Bucher A, Höltl W, Albrecht W, Havelec L. Topische Immuntherapie (KLH) vs. Chemotherapie (Ethoglucid) in der Rezidivprophylaxe oberflächlicher Harnblasenkarzinome. Eine prospektiv randomisierte Studie [Topical immunotherapy (KLH) vs. chemotherapy (Ethoglucid) in prevention of recurrence of superficial bladder cancer. A prospective randomized study]. Urologe A. 1994 Mar;33(2):138-43. German. PMID: 8178408.
2: Thrasher JB, Crawford ED. Complications of intravesical chemotherapy. Urol Clin North Am. 1992 Aug;19(3):529-39. PMID: 1636237.
3: Sonneveld P, Kurth KH, Hagemeyer A, Abels J. Secondary hematologic neoplasm after intravesical chemotherapy for superficial bladder carcinoma. Cancer. 1990 Jan 1;65(1):23-5. doi: 10.1002/1097-0142(19900101)65:1<23::aid- cncr2820650107>3.0.co;2-q. PMID: 2104570.
4: Veenema RJ, Romas NA, Fingerhut B. Chemotherapy for bladder cancer. Urology. 1974 Feb;3(2):135-9. doi: 10.1016/s0090-4295(74)80001-4. PMID: 4204755.
5: Condon HA. Hypothermia and cancer chemotherapy. Anesth Analg. 1969 Jan- Feb;48(1):92-8. PMID: 5812564.
6: Soloway MS. Intravesical and systemic chemotherapy of murine bladder cancer. Cancer Res. 1977 Aug;37(8 Pt 2):2918-29. PMID: 406041.
7: Schmidt CG. Alkylierende cytostatica [Alkylating cytostatic agents]. Internist (Berl). 1971;12:Suppl 1:119-27. German. PMID: 5002874.
8: Torti FM, Lum BL. The biology and treatment of superficial bladder cancer. J Clin Oncol. 1984 May;2(5):505-31. doi: 10.1200/JCO.1984.2.5.505. PMID: 6427417.
9: Highley MS, van Oosterom AT, Maes RA, De Bruijn EA. Intravesical drug delivery. Pharmacokinetic and clinical considerations. Clin Pharmacokinet. 1999 Jul;37(1):59-73. doi: 10.2165/00003088-199937010-00004. PMID: 10451783.
10: Flamm J, Kühnel W, Dona S. Kurzzeit- versus Langzeitchemorezidivprophylaxe mit Epodyl nach TUR beim oberflächlichen Harnblasenkarzinom [Short-term versus long-term chemoprevention of recurrence with Epodyl following transurethral resection of superficial urinary bladder cancer]. Urologe A. 1989 Mar;28(2):99-102. German. PMID: 2655259.
